# Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

> **NCT07185373** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Huashan Hospital** · enrollment: 215 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Teniposide
- **DRUG:** Orelabrutinib
- **DRUG:** MTX
- **DRUG:** Rituximab (R)
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07185373
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-07-30
- **Target enrollment:** 215 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185373, "Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07185373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*